AWH
Income statement / Annual
Last year (2023), Aspira Women's Health Inc.'s total revenue was $9.15 M,
an increase of 11.85% from the previous year.
In 2023, Aspira Women's Health Inc.'s net income was -$16.69 M.
See Aspira Women's Health Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$9.15 M |
$8.18 M |
$6.81 M |
$4.65 M |
$4.54 M |
$3.05 M |
$3.12 M |
$2.64 M |
$2.18 M |
$2.52 M |
| Cost of Revenue |
$3.89 M
|
$3.87 M
|
$3.75 M
|
$3.42 M
|
$3.34 M
|
$3.14 M
|
$2.91 M
|
$2.70 M
|
$2.31 M
|
$1.23 M
|
| Gross Profit |
$5.26 M
|
$4.32 M
|
$3.06 M
|
$1.24 M
|
$1.20 M
|
-$89,000.00
|
$207,000.00
|
-$56,000.00
|
-$132,000.00
|
$1.29 M
|
| Gross Profit Ratio |
0.57
|
0.53
|
0.45
|
0.27
|
0.26
|
-0.03
|
0.07
|
-0.02
|
-0.06
|
0.51
|
| Research and Development Expenses |
$4.04 M
|
$5.95 M
|
$5.31 M
|
$2.10 M
|
$1.02 M
|
$550,000.00
|
$837,000.00
|
$2.17 M
|
$3.75 M
|
$4.67 M
|
| General & Administrative Expenses |
$12.27 M
|
$16.18 M
|
$13.26 M
|
$8.27 M
|
$5.81 M
|
$5.05 M
|
$5.54 M
|
$5.93 M
|
$5.53 M
|
$5.94 M
|
| Selling & Marketing Expenses |
$7.81 M
|
$14.95 M
|
$17.09 M
|
$8.84 M
|
$9.65 M
|
$5.64 M
|
$4.27 M
|
$6.80 M
|
$9.83 M
|
$9.89 M
|
| Selling, General & Administrative Expenses |
$20.08 M
|
$31.13 M
|
$30.34 M
|
$17.11 M
|
$15.46 M
|
$10.69 M
|
$9.81 M
|
$12.73 M
|
$15.37 M
|
$15.84 M
|
| Other Expenses |
$0.00
|
$106,000.00
|
$981,000.00
|
$66,000.00
|
-$18,000.00
|
-$16,000.00
|
-$14,000.00
|
$14,000.00
|
$106,000.00
|
-$38,000.00
|
| Operating Expenses |
$24.11 M
|
$37.08 M
|
$35.66 M
|
$19.22 M
|
$16.47 M
|
$11.24 M
|
$10.65 M
|
$14.90 M
|
$19.12 M
|
$20.50 M
|
| Cost And Expenses |
$28.01 M
|
$40.95 M
|
$39.41 M
|
$22.63 M
|
$19.82 M
|
$14.39 M
|
$13.56 M
|
$17.60 M
|
$21.43 M
|
$21.73 M
|
| Interest Income |
$48,000.00
|
$17,000.00
|
$48,000.00
|
$10,000.00
|
$59,000.00
|
$0.00
|
$0.00
|
$0.00
|
$28,000.00
|
$40,000.00
|
| Interest Expense |
$0.00
|
$17,000.00
|
$48,000.00
|
$0.00
|
$59,000.00
|
$22,000.00
|
$42,000.00
|
$28,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$199,000.00
|
$269,000.00
|
$339,000.00
|
$291,000.00
|
$333,000.00
|
$675,000.00
|
$786,000.00
|
$723,000.00
|
$291,000.00
|
$141,000.00
|
| EBITDA |
-$16.49 M |
-$30.87 M |
-$32.29 M |
-$17.72 M |
-$14.95 M |
-$10.66 M |
-$9.66 M |
-$14.23 M |
-$18.96 M |
-$19.07 M |
| EBITDA Ratio |
-1.8
|
-4.67
|
-4.74
|
-3.87
|
-3.37
|
-3.71
|
-3.35
|
-5.66
|
-8.84
|
-7.62
|
| Operating Income Ratio |
-2.06
|
-4
|
-4.78
|
-3.87
|
-3.37
|
-3.71
|
-3.35
|
-5.66
|
-8.84
|
-7.62
|
| Total Other Income/Expenses Net |
$2.16 M
|
$1.25 M
|
$933,000.00
|
$76,000.00
|
$41,000.00
|
-$38,000.00
|
-$56,000.00
|
-$14,000.00
|
$134,000.00
|
$2,000.00
|
| Income Before Tax |
-$16.69 M
|
-$27.17 M
|
-$31.66 M
|
-$17.91 M
|
-$15.24 M
|
-$11.37 M
|
-$10.50 M
|
-$14.97 M
|
-$19.12 M
|
-$19.21 M
|
| Income Before Tax Ratio |
-1.82
|
-3.32
|
-4.65
|
-3.85
|
-3.36
|
-3.72
|
-3.36
|
-5.67
|
-8.78
|
-7.62
|
| Income Tax Expense |
$0.00
|
-$5.60 M
|
$48,000.00
|
-$275,000.00
|
-$392,000.00
|
-$38,000.00
|
-$744,000.00
|
-$695,000.00
|
-$319,000.00
|
-$181,000.00
|
| Net Income |
-$16.69 M
|
-$21.58 M
|
-$31.71 M
|
-$17.63 M
|
-$14.85 M
|
-$11.37 M
|
-$10.50 M
|
-$14.97 M
|
-$19.12 M
|
-$19.21 M
|
| Net Income Ratio |
-1.82
|
-2.64
|
-4.66
|
-3.79
|
-3.27
|
-3.72
|
-3.36
|
-5.67
|
-8.78
|
-7.62
|
| EPS |
-1.81 |
-41.66 |
-4.28 |
-2.63 |
-2.57 |
-2.43 |
-2.77 |
-4.35 |
-6.15 |
-7.99 |
| EPS Diluted |
-1.81 |
-41.66 |
-4.28 |
-2.63 |
-2.57 |
-2.43 |
-2.77 |
-4.3 |
-6.08 |
-7.99 |
| Weighted Average Shares Out |
$9.23 M
|
$517,940.00
|
$7.41 M
|
$6.71 M
|
$5.77 M
|
$4.67 M
|
$3.80 M
|
$3.44 M
|
$3.11 M
|
$2.41 M
|
| Weighted Average Shares Out Diluted |
$9.23 M
|
$517,940.00
|
$7.41 M
|
$6.71 M
|
$5.77 M
|
$4.67 M
|
$3.80 M
|
$3.48 M
|
$3.14 M
|
$2.41 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
